Coffee and Cancer Risk

Slideshow

This slide show highlights recent studies that examined coffee consumption as it relates to cancer risk, including melanoma, breast and liver cancers, and more.

References:

1. Holick CN, Smith SG, Giovannucci E, Michaud DS. Coffee, Tea, Caffeine Intake, and Risk of Adult Glioma in Three Prospective Cohort Studies. Cancer Epidemiol Biomarkers Prev. 2010;19:39-47.

2. Galeone C, Tavani A, Pelucchi C, et al. Coffee and tea intake and risk of head and neck cancer: pooled analysis in the international head and neck cancer epidemiology consortium. Cancer Epidemiol Biomarkers Prev. 2010;19:1723-36.

3. Setiawan VW, Wilkens LR, Hernandez BY, et al. Coffee intake reduces hepatocellular carcinoma risk: The Multiethnic Cohort. American Association for Cancer Research Annual Meeting 2014; April 5–9, 2014; San Diego. Abstr LB-281.

4. Geybels MS, Neuhouser ML, Wright JL, et al. Coffee and tea consumption in relation to prostate cancer prognosis. Cancer Causes Control. 2013;24:1947-54.

5. Sinha R, Cross AJ, Daniel CR, et al. Caffeinated and decaffeinated coffee and tea intakes and risk of colorectal cancer in a large prospective study. Am J Clin Nutr. 2012;96:374-81.

6. Jiang W, Wu Y, Jiang X. Coffee and caffeine intake and breast cancer risk: an updated dose-response meta-analysis of 37 published studies. Gynecol Oncol. 2013;129:620-9.

7. Loftfield E, Freedman ND, Graubard BI, et al. Coffee drinking and cutaneous melanoma risk in the NIH-AARP diet and health study. J Natl Cancer Inst. 2015 Jan 20. Epub ahead of print.

8. Merritt MA, Tzoulaki I, Tworoger SS, et al. Investigation of Dietary Factors and Endometrial Cancer Risk Using a Nutrient-wide Association Study Approach in the EPIC and Nurses' Health Study (NHS) and NHSII. Cancer Epidemiol Biomarkers Prev. 2015;24:466-71.

Recent Videos
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Related Content